MX2017009181A - Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer. - Google Patents

Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.

Info

Publication number
MX2017009181A
MX2017009181A MX2017009181A MX2017009181A MX2017009181A MX 2017009181 A MX2017009181 A MX 2017009181A MX 2017009181 A MX2017009181 A MX 2017009181A MX 2017009181 A MX2017009181 A MX 2017009181A MX 2017009181 A MX2017009181 A MX 2017009181A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
sccars
cancer immunotherapy
specific single
Prior art date
Application number
MX2017009181A
Other languages
English (en)
Inventor
Smith Julianne
Duchateau Philippe
Juillerat Alexandre
Johnson Sasu Barbra
Rajpal Arvind
Valton Julien
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Publication of MX2017009181A publication Critical patent/MX2017009181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1028—Sorting particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente invención se refiere a Receptores de Antígenos Quiméricos (CAR) que son proteínas quiméricas recombinantes capaces de redirigir la especificidad y reactividad de las células inmunitarias hacia células CLL1-positivas. Las células inmunitarias genéticamente manipuladas dotadas de dichos CARs son particularmente adecuadas para la inmunoterapia para el tratamiento de cáncer, en particular leucemia.
MX2017009181A 2015-01-26 2016-01-25 Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer. MX2017009181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570044 2015-01-26
PCT/EP2016/051469 WO2016120218A1 (en) 2015-01-26 2016-01-25 ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
MX2017009181A true MX2017009181A (es) 2017-11-22

Family

ID=52396337

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017009349A MX2017009349A (es) 2015-01-26 2016-01-25 Celulas inmunitarias geneticamente manipuladas para inactivacion de receptor de cleulas t, dotadas con receptores de antigenos quimericos de union a cd123 para el tratamiento de linfoma mieloide agudo o neoplasia de celulas dendriticas plasmacitoides blasticas recidivante/refractaria.
MX2017009181A MX2017009181A (es) 2015-01-26 2016-01-25 Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
MX2017009182A MX2017009182A (es) 2015-01-26 2016-01-25 Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009349A MX2017009349A (es) 2015-01-26 2016-01-25 Celulas inmunitarias geneticamente manipuladas para inactivacion de receptor de cleulas t, dotadas con receptores de antigenos quimericos de union a cd123 para el tratamiento de linfoma mieloide agudo o neoplasia de celulas dendriticas plasmacitoides blasticas recidivante/refractaria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017009182A MX2017009182A (es) 2015-01-26 2016-01-25 Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.

Country Status (14)

Country Link
US (6) US20180002435A1 (es)
EP (5) EP3250607A1 (es)
JP (5) JP6779909B2 (es)
KR (3) KR20170135824A (es)
CN (5) CN107531801B (es)
AU (5) AU2016212159A1 (es)
BR (3) BR112017013981A2 (es)
CA (5) CA2973524A1 (es)
DK (2) DK3250604T3 (es)
ES (2) ES2842212T3 (es)
IL (3) IL252937B (es)
MX (3) MX2017009349A (es)
RU (3) RU2732925C2 (es)
WO (5) WO2016120217A1 (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
RU2727290C2 (ru) * 2014-03-19 2020-07-21 Селлектис Cd123-специфические химерные антигенные рецепторы для иммунотерапии рака
SG11201707089WA (en) 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US10709775B2 (en) * 2015-08-11 2020-07-14 Cellectis Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
MA43135A (fr) * 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
CN105331586B (zh) * 2015-11-20 2020-09-15 上海细胞治疗研究院 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
US11072662B2 (en) 2015-11-24 2021-07-27 Cellerant Therapeutics, Inc. Humanized anti-CLL-1 antibodies
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Federale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11787848B2 (en) 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
US11466291B2 (en) 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
CA3034324A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
WO2018057915A1 (en) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Engineered lymphocytes
AU2017338846B2 (en) * 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
CN110662554A (zh) 2017-02-28 2020-01-07 Vor生物制药股份有限公司 用于抑制谱系特异性蛋白质的组合物和方法
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3592379B1 (en) * 2017-03-31 2024-04-24 Cellectis SA Universal anti-cd22 chimeric antigen receptor engineered immune cells
WO2018183927A1 (en) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3621981A2 (en) 2017-05-12 2020-03-18 CRISPR Therapeutics AG Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018222935A1 (en) * 2017-06-02 2018-12-06 Pfizer Inc. Chimeric antigen receptors targeting flt3
CA3065930A1 (en) 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
SG10202109108UA (en) * 2017-06-21 2021-09-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
EP3645036A1 (en) 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
US11479606B2 (en) 2017-07-20 2022-10-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CD33-expressing cancers
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
AU2018306307A1 (en) * 2017-07-25 2020-02-20 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109836496A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109837303A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
US10785574B2 (en) 2017-12-14 2020-09-22 Flodesign Sonics, Inc. Acoustic transducer driver and controller
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
CN109608548A (zh) * 2017-12-29 2019-04-12 郑州大学第附属医院 基于人源cd20抗体的嵌合抗原受体、慢病毒表达载体及其应用
JP7372920B2 (ja) 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
CA3088878A1 (en) * 2018-01-09 2019-07-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for targeting clec12a-expressing cancers
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
JP7526101B2 (ja) 2018-03-02 2024-07-31 アロジーン セラピューティクス，インコーポレイテッド 誘導性キメラサイトカイン受容体
EP3765514A1 (en) * 2018-03-14 2021-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd33 chimeric antigen receptors and their uses
JP2021518411A (ja) * 2018-03-21 2021-08-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｆｃバリアント組成物およびその使用方法
CN108530536B (zh) * 2018-03-27 2021-08-13 刘爽 Cart-cd123及其制备与应用
CN108531457A (zh) * 2018-04-10 2018-09-14 杭州荣泽生物科技有限公司 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法
BR112020020919A2 (pt) 2018-04-13 2021-04-06 Sangamo Therapeutics France Receptor de antígeno quimérico específico para receptor de interleucina-23
PE20210666A1 (es) 2018-05-11 2021-03-31 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer
US12054558B2 (en) 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
CN112243444A (zh) 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
KR20210089179A (ko) * 2018-10-26 2021-07-15 카파 테라퓨틱스 리미티드 Cll1을 표적으로 하는 항체 및 이의 응용
MX2021006395A (es) 2018-12-01 2021-07-15 Allogene Therapeutics Inc Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso.
CA3131908A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
JP2022522654A (ja) 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
AU2020232597A1 (en) 2019-03-01 2021-08-19 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN113811327A (zh) * 2019-03-11 2021-12-17 卢西德生物有限公司 MUC1平行CAR(pCAR)治疗剂
WO2020191378A1 (en) 2019-03-21 2020-09-24 Allogene Therapeutics, Inc. METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
US11090336B2 (en) * 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
CA3136618A1 (en) 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
FI3959235T3 (fi) 2019-04-26 2023-09-27 Allogene Therapeutics Inc Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö
CA3132509A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
JP2022538397A (ja) * 2019-06-19 2022-09-02 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク キメラ抗原受容体設計で実施するためのウルトラモジュラー（ｕｌｔｒａｍｏｄｕｌａｒ） ＩｇＧ３ベーススペーサードメイン及び多機能部位
CN112111013A (zh) * 2019-06-22 2020-12-22 南京北恒生物科技有限公司 一种靶向claudin 18.2的通用型嵌合抗原受体T细胞、构建方法及其用途
CN114829399A (zh) * 2019-07-09 2022-07-29 海默珍科医药有限责任公司 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
BR112022003553A2 (pt) 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
EP4038190A1 (en) 2019-10-03 2022-08-10 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
KR20220118532A (ko) 2019-12-23 2022-08-25 셀렉티스 고형 종양들 암 면역요법을 위한 새로운 메소텔린 특이적 키메라 항원 수용체들 (car)
TW202140533A (zh) 2020-01-16 2021-11-01 美商異基因治療有限公司 靶向B 細胞成熟抗原之嵌合抗原受體及γ 分泌酵素抑制劑之組合療法
EP4110805A1 (en) 2020-02-24 2023-01-04 Allogene Therapeutics, Inc. Bcma car-t cells with enhanced activities
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
IL296176A (en) * 2020-03-06 2022-11-01 Purdue Research Foundation Methods, compounds and compositions for altering car-t cell activity
WO2021188631A1 (en) * 2020-03-18 2021-09-23 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
IL296511A (en) 2020-03-20 2022-11-01 Lyell Immunopharma Inc New recombinant cell surface markers
JP2023523890A (ja) * 2020-03-27 2023-06-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｓｐ７０を標的とするモノクローナル抗体およびその治療的使用
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
KR20210136879A (ko) * 2020-05-08 2021-11-17 (주)에스엠티바이오 암 치료를 위한 키메라 항원 수용체
CN113735973B (zh) * 2020-05-28 2023-05-09 中国科学院微生物研究所 一种抗SIRPα抗体及其应用
EP4176261A1 (en) 2020-07-03 2023-05-10 Cellectis S.A. Method for determining potency of chimeric antigen receptor expressing immune cells
CA3185197A1 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
EP4185616A1 (en) 2020-07-24 2023-05-31 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
US20220041999A1 (en) * 2020-08-07 2022-02-10 Neogene Therapeutics B.V. Methods to enrich genetically engineered t cells
CN112079927B (zh) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 一种cd123结合蛋白、含其的car及其应用
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113896795B (zh) * 2020-12-11 2022-07-15 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113248622B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 一种靶向cll1和nkg2d配体的双靶点嵌合抗原受体及其应用
EP4259782A1 (en) 2020-12-14 2023-10-18 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CA3206883A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN112661816B (zh) * 2021-01-13 2022-10-11 江西省人民医院 用于利妥昔单抗血药浓度检测的人工抗原及试剂盒
JP2024508223A (ja) 2021-01-28 2024-02-26 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞を形質導入する方法
EP4284918A1 (en) 2021-01-29 2023-12-06 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
IL308012A (en) * 2021-04-30 2023-12-01 Cellectis Sa Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy
EP4419672A2 (en) 2021-06-01 2024-08-28 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
US20220409665A1 (en) 2021-06-15 2022-12-29 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
CN115477704B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
WO2022266538A2 (en) 2021-06-18 2022-12-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2023020471A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies and uses thereof in cancer therapies
WO2023125289A1 (zh) * 2021-12-31 2023-07-06 上海宏成药业有限公司 抗pd-1抗体及其用途
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
US20230346934A1 (en) 2022-03-29 2023-11-02 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2023201238A1 (en) 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024051751A1 (zh) * 2022-09-06 2024-03-14 河北森朗生物科技有限公司 抗cd123的纳米抗体、嵌合抗原受体及其应用
WO2024064754A1 (en) * 2022-09-20 2024-03-28 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted degradation and delivery of therapeutic agents
WO2024118593A1 (en) 2022-11-28 2024-06-06 Allogene Therapeutics Inc. Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
WO2024121385A1 (en) 2022-12-09 2024-06-13 Cellectis S.A. Two-dose regimen in immunotherapy

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994024277A1 (en) 1993-04-13 1994-10-27 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DE60130435T2 (de) 2000-02-24 2009-07-23 Invitrogen Corp., Carlsbad Gleichzeitige stimulation und konzentration von zellen
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1319023B8 (en) 2000-09-13 2009-07-15 multimmune GmbH An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EA010570B1 (ru) 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
HUE035898T2 (en) * 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
CN1826408B (zh) 2003-03-14 2011-01-26 塞托·帕尔斯科技公司 大容量离体电穿孔法
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005054295A2 (en) 2003-12-05 2005-06-16 Multimmune Gmbh Therapeutic and diagnostic anti-hsp 70 antibodies
WO2005077982A1 (en) * 2004-02-16 2005-08-25 Micromet Ag Less immunogenic binding molecules
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
GB0505971D0 (en) 2005-03-23 2005-04-27 Isis Innovation Delivery of molecules to a lipid bilayer
CA2618482C (en) 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
JP2009508517A (ja) * 2005-09-22 2009-03-05 コーエン，イルン，アール Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド
EP2122344B8 (en) 2007-02-20 2019-08-21 Oxford Nanopore Technologies Limited Lipid bilayer sensor system
CA2967847C (en) 2007-03-30 2023-08-01 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2211903A4 (en) * 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EP3006459B1 (en) 2008-08-26 2021-10-06 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
ES2656414T3 (es) 2010-09-08 2018-02-27 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
EP2614151B1 (en) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
AU2011319725A1 (en) 2010-10-27 2013-05-30 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
SG189914A1 (en) * 2010-10-27 2013-06-28 Baxter Int Fviii peptides for immune tolerance induction and immunodiagnostics
LT3214091T (lt) 2010-12-09 2018-12-10 The Trustees Of The University Of Pennsylvania Modifikuotų t ląstelių, turinčių chimerinį antigeno receptorių, panaudojimas vėžio gydymui
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
SG193023A1 (en) 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
US8968539B2 (en) 2011-03-08 2015-03-03 Electronic Biosciences, Inc. Methods for voltage-induced protein incorporation into planar lipid bilayers
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
DK2694091T3 (da) 2011-04-05 2019-06-03 Cellectis Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf
US9266960B2 (en) 2011-04-08 2016-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
US9285592B2 (en) 2011-08-18 2016-03-15 Google Inc. Wearable device with input and output structures
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
EP2765193B1 (en) 2011-10-07 2017-08-09 Mie University Chimeric antigen receptor
IL296507A (en) * 2011-10-10 2022-11-01 Hope City Meditops and Meditop binding antibodies and their use
CN103946242A (zh) 2011-10-20 2014-07-23 美国卫生和人力服务部 抗cd22嵌合抗原受体
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
AU2012339618B2 (en) * 2011-11-15 2017-09-07 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104159917A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 使用icos基cars增强抗肿瘤活性和car持久性
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
AU2013222284A1 (en) 2012-02-22 2014-08-07 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
MX2018008352A (es) * 2012-04-11 2022-08-10 Us Health Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
MY180127A (en) 2012-05-25 2020-11-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
SG11201408398UA (en) 2012-07-13 2015-02-27 Univ Pennsylvania Compositions and methods for regulating car t cells
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
CN104769103B (zh) * 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2958942B1 (en) * 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP2968502B1 (en) 2013-03-14 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
PT2997141T (pt) 2013-05-13 2022-11-23 Cellectis Recetor de antigénio quimérico específico para cd19 e utilizações do mesmo
EP2997133B1 (en) 2013-05-13 2023-08-23 Cellectis Methods for engineering highly active t cell for immunotherapy
EP3309248B1 (en) * 2013-05-29 2021-06-09 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
KR20210115051A (ko) * 2013-06-10 2021-09-24 다나-파버 캔서 인스티튜트 인크. 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
PL3071223T3 (pl) 2013-11-21 2021-08-16 Autolus Limited Komórka
MX2016006177A (es) 2013-11-22 2016-08-19 Cellectis Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3083671B1 (en) * 2013-12-20 2020-09-30 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
WO2015123527A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
RU2727290C2 (ru) * 2014-03-19 2020-07-21 Селлектис Cd123-специфические химерные антигенные рецепторы для иммунотерапии рака
WO2015158671A1 (en) * 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
SG11201700418VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
IL290459B2 (en) 2014-12-05 2023-11-01 Hope City Modified T cells - CS1-targeted chimeric antigen receptor
SG11201707089WA (en) 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
US9668192B2 (en) 2015-10-12 2017-05-30 Telefonaktiebolaget Lm Ericsson (Publ) Cell boundary crossing in a unidirectional SFN for high speed trains

Also Published As

Publication number Publication date
BR112017015453A2 (pt) 2018-01-23
AU2016212158B2 (en) 2021-06-03
US20180000914A1 (en) 2018-01-04
CA2973529A1 (en) 2016-08-04
US20180002435A1 (en) 2018-01-04
MX2017009349A (es) 2017-09-26
CN107406516B (zh) 2021-11-23
JP2018504144A (ja) 2018-02-15
US20180002427A1 (en) 2018-01-04
US11014989B2 (en) 2021-05-25
WO2016120219A1 (en) 2016-08-04
JP6884709B2 (ja) 2021-06-09
EP3250602A1 (en) 2017-12-06
KR20170134331A (ko) 2017-12-06
IL253049B (en) 2022-01-01
EP3250607A1 (en) 2017-12-06
MX2017009182A (es) 2018-04-20
CN113968914A (zh) 2022-01-25
RU2731543C2 (ru) 2020-09-04
CA2973532A1 (en) 2016-08-04
WO2016120216A1 (en) 2016-08-04
EP3250604B1 (en) 2021-04-21
JP6779909B2 (ja) 2020-11-04
KR20170135822A (ko) 2017-12-08
JP2018504145A (ja) 2018-02-15
CN107531801A (zh) 2018-01-02
KR20170135824A (ko) 2017-12-08
WO2016120220A1 (en) 2016-08-04
RU2017129591A3 (es) 2019-08-05
CN107531801B (zh) 2021-11-12
CN107406516A (zh) 2017-11-28
ES2869972T3 (es) 2021-10-26
CA2973642A1 (en) 2016-08-04
RU2017129455A (ru) 2019-03-04
US20240228636A1 (en) 2024-07-11
CA2973525A1 (en) 2016-08-04
RU2017129592A (ru) 2019-02-28
JP2018504143A (ja) 2018-02-15
BR112017013981A2 (pt) 2018-01-02
DK3250606T3 (da) 2021-01-04
AU2016212160B2 (en) 2021-04-15
RU2017129592A3 (es) 2019-07-17
JP2018504459A (ja) 2018-02-15
EP3250604A1 (en) 2017-12-06
AU2016212162A1 (en) 2017-07-13
RU2017129591A (ru) 2019-03-04
CN113968915A (zh) 2022-01-25
AU2016212159A1 (en) 2017-07-13
IL252937A0 (en) 2017-08-31
IL253012A0 (en) 2017-08-31
KR102661969B1 (ko) 2024-04-29
RU2732925C2 (ru) 2020-09-24
JP2018504458A (ja) 2018-02-15
US20180051089A1 (en) 2018-02-22
CA2973524A1 (en) 2016-08-04
KR102329836B1 (ko) 2021-11-19
BR112017014547A2 (pt) 2018-01-16
US20180009895A1 (en) 2018-01-11
IL253049A0 (en) 2017-08-31
DK3250604T3 (da) 2021-07-12
CA2973525C (en) 2021-12-14
RU2017129455A3 (es) 2019-08-15
EP3250605A1 (en) 2017-12-06
AU2016212161A1 (en) 2017-07-13
WO2016120218A1 (en) 2016-08-04
CN107438618A (zh) 2017-12-05
EP3250606B1 (en) 2020-11-25
IL252937B (en) 2021-09-30
WO2016120217A1 (en) 2016-08-04
EP3250606A1 (en) 2017-12-06
ES2842212T3 (es) 2021-07-13
AU2016212158A1 (en) 2017-07-13
AU2016212160A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
MX2017009181A (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
MX2019012244A (es) Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
MX2016012855A (es) Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.
MX2017001211A (es) Receptores de antigenos quimericos ror1 (ntrkr1) especificos para inmunoterapia del cancer.
MX2017001229A (es) Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
MX2023001403A (es) Neoantigenos y metodos de su uso.
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
PH12016502491A1 (en) Bispecific heterodimeric diabodies and uses thereof
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
PH12015501880A1 (en) Compositions and methods for immunotherapy
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
SG10201909716RA (en) Modified j-chain
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12018501902A1 (en) Gitr antibodies, methods, and uses
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
TN2015000415A1 (en) Anti-cd52 antibodies
MX2016011748A (es) Anticuerpos humanizados con estabilidad incrementada.
MX2020000595A (es) Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.
NZ725519A (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3